関連する実験動画
Updated: Sep 9, 2025
08:58
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
16.1K
統合されたスクリーニングでは,GPR31が代謝機能障害に関連するステアト肝炎の主要な誘発因子であり,薬物投与可能な標的であることが確認された
Xiao-Jing Zhang1,2, Jiajun Fu1, Xu Cheng1
1State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Gannan Innovation and Translational Medicine Research Institute, School of Pharmacy, First Affiliated Hospital, Gannan Medical University, Ganzhou, China.
The Journal of clinical investigation
|September 2, 2025
まとめ
研究者らは,GPR31を代謝機能障害関連ステアト肝炎 (MASH) の主要な原動力として特定した. 新薬候補G4451でGPR31を抑制することで,臨床前モデルにおいてMASHの進行を効果的に阻害し,有望な新しい治療戦略を提供した.
科学分野:
- ヘパトロジー
- 分子生物学
- 薬理学について
背景:
- メタボリック機能障害に関連したステアトヘパチス (MASH) は,治療の選択肢が限られている一般的な肝疾患です.
- 新しい病原性遺伝子と治療標的を特定することはMASHの管理に不可欠です.
研究 の 目的:
- 統合スクリーニングを行い,MASHの遺伝子と標的を特定する.
- MASHの病原性におけるGPR31の役割を調査する.
- GPR31を標的とするMASHの治療戦略を策定し評価する.
主な方法:
- 多層のスクリーニングでMASHの病原性遺伝子と薬剤の標的を特定します
- Gαi3とPKCδ-MAPKのシグナル伝達を含むGPR31のメカニズムを調査した.
- 肝細胞特異のGPR31ノックアウトとトランスジェニックマウスモデルを使用した.
- 小分子阻害剤G4451をネズミとヒト以外の霊長類のMASHモデルで開発し,試験した.
主要な成果:
- GPR31は,MASHに以前は特徴づけられていなかった重要な寄与因子として特定されました.
- GPR31は,PKCδ-MAPKシグナル伝達のGαi3依存の活性化によってMASHを促進する.
- 肝細胞特有のGPR31欠乏はMASHを改善し,過剰発現は状態を悪化させた.
- G4451は特にGPR31- Gαi3の相互作用を抑制し,臨床前モデルではMASHの進行を阻害した.
結論:
- GPR31はMASHの重要な治療標的である.
- GPR31- Gαi3とG4451の相互作用をターゲットにすると,MASHの治療の可能性が顕著である.
- GPR31への干渉はMASH治療の有望な戦略です.
関連する概念動画
01:15G Protein-coupled Receptors
13.3K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
13.3K
01:24Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.8K
01:09GPCRs Regulate Adenylyl Cylase Activity
5.9K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.9K
01:26Targets for Drug Action: Overview
7.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.4K
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
79
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
79